The FDA approved Alzheimer’s disease drug aducanumab despite minimal evidence of its efficacy. Whether this decision ultimately hurts or helps patients depends on data researchers don’t yet have.
Academic rigor, journalistic flair
Articles on Health insurance
Displaying 41 - 60 of 135 articles
Both are essential on a farm, but the costs are making it harder for young farmers to grow their businesses.
The US health system costs roughly twice as much as the Australian system per person. Despite this, the US has lower life expectancy than Australia.
Often the main differences among plans involve a long list of varying deductibles, co-pays and other out-of-pocket expenses, which can be tough to analyze.
New Zealanders have, in principle, access to free healthcare. But inequality is a major issue, affecting Māori and Pasifika communities and New Zealanders living with disabilities or in poverty.
For millions, the ACA is making a big difference during the coronavirus crisis.
COVID-19 cases among college students are inevitable. If you’re a college student – or the parent of one – you need to know who’s going to foot the bill if they get sick.
Studies repeatedly have shown that health care in general and the high cost of drugs in particular are among the top concerns of US voters. But with coronavirus, the issue may fade from prominence.
Help is out there for those many who have lost health insurance because of the pandemic. You can thank Obamacare.
COVID19 threatens to reverse years of Indonesia’s positive trends in poverty alleviation. We highlight lessons from past policies to prevent another poverty hike during the pandemic.
The pandemic magnifies existing imbalances in wealth, access to health care and workplace rights.
In the UK, nobody collects patients’ insurance information or credit card details. There’s simply no charge for services, including doctor visits, ambulances and hospitalizations.
Ghana’s lack of a palliative care policy is posing a significant challenge to effective healthcare for cancer patients.
It’s not the price of health care that should concern us. It’s the cost. There’s a distinction, and it matters. Here’s why.
High prescription drug costs are a widespread concern for consumers and policymakers. For patients who need specialty drugs, though, the problem is even worse, with no relief in sight.
In the wake of the New Deal, the business community realized that appealing to widely shared American values could get the public to oppose measures that curbed corporate power.
Young people don’t see the value in private health insurance and are dropping their cover in droves. Allowing under 55s to pay lower premiums, based on their lower risk, could keep them in the system.
Just how big a problem are medical bankruptcies? For someone going through one, it’s devastating. And it happens far more often than you might think.
Patients often want the option to be treated at home rather than being admitted to hospital. But it’s much less likely to happen if you’re a private patient.
Nearly 160 million Americans get insurance through employers, but that does not mean it’s good social policy. An economist explains some aspects of employer-sponsored insurance that don’t work well.
Top contributors
-
Associate Professor of Public Health, Texas A&M University
-
Professor of Health Finance, Weatherhead School of Management & School of Medicine, Case Western Reserve University
-
Assistant Professor of Health Law, Policy and Management, Boston University
-
Honorary Enterprise Professor, School of Population and Global Health, and Department of General Practice and Primary Care, The University of Melbourne
-
Research Scientist and Director of Research Training in Health Policy and Economics, University of Southern California
-
Research Assistant Professor of Social, Behavioral and Population Sciences, Tulane University
-
Professor of Health Law and Bioethics, Case Western Reserve University
-
Assistant Professor of Health Economics, University of Toronto
-
Assistant Professor of Economics, University of California, Berkeley
-
Postdoctoral researcher of Health Policy and Economics, University of Southern California
-
Professor, Department of Health Policy, London School of Economics and Political Science
-
Quintiles Professor of Pharmaceutical Development and Regulatory Innovation, Schaeffer Center for Health Policy and Economics, University of Southern California
-
Professor, Public Health, Victoria University, Victoria University
-
Lecturer, Public Sector Finance, University of Canberra
-
Associate Professor of Health Policy, Management and Behavior, University at Albany, State University of New York
